Organic revenue growth of +2% supported by Care Enablement and Care Delivery Underlying U.S. dialysis treatment volume growth turns positive Exceeding full year FME25 savings target, with additional EUR 64 million contribution in Q3 Both segments further increased operating income1 and operating income margin1 Net financial leverage ratio further improved to 2.8x FY 2024 operating income1 growth outlook with 16-18% tightened toward the upper end of the previous rangeBAD HOMBURG, Germany, Nov. 5, 2024 /PRNe ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional val ...

A dedicated session will highlight new advancements in hemodiafiltration therapy showcasing its potential to improve patient outcomes through enhanced toxin removal in dialysis treatments.Company-wide researchers and clinical experts share insights from large global databases, revealing crucial trends in kidney failure etiology, cardiovascular risks, and treatment modalities across different regions.Nearly 75 abstracts presented across a broad range of cutting-edge research, covering topics from the global ...

Analyst's Disclosure: I/we have a beneficial long position in the shares of FMS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. While this article may sound like financial advice, please observe that the author is not a CFA or in any way licensed to give financial advice ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...

Fresenius Medical Care (FMS) is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Through its network of more than 3,600 clinics across the world, the company offers dialysis services and products in more than 120 countries and employs over 109,000 staff in more than 50 countries. Fresenius Medical reports through two segments — Care Delivery and Care Enablement. The Care Delivery segment consists of the company's Dialysis ...

Fresenius Medical Care AG& Co (FMS) announced the launch of the newest version of its home dialysis machine, NxStage Versi HD, with GuideMe Software. This new system simplifies treatment, enhances user experience and accelerates training. The company stated that it has reached a key milestone with over 14,000 United States patients using its NxStage system for Home Hemodialysis (HHD). Following the announcement on Sept. 4, shares of the company were up 1% as of Sept. 6. Significance of Fresenius Medical Car ...

Fresenius Medical Care achieves growth milestone of more than 14,000 U.S.-based patients using the Company's NxStage systems to perform Home Hemodialysis therapy This growth has generated greater adoption from a range of dialysis providers and delivers on the company's commitment to grow access to and use of home dialysis therapy The newest NxStage® Versi®HD with GuideMe Software home dialysis machine is designed to simplify treatment, increase ease of learning, and improve user experience WALTHAM, Mass., S ...

Fresenius Medical Care AG & Co. KGaA (FMS) is well-poised for growth on the back of a broad range of dialysis products and services, and a solid global foothold. However, stiff competition remains a concern. Shares of this Zacks Rank #3 (Hold) company have lost 5.6% year to date against the industry's growth of 9.4%. The S&P 500 Index has increased 18.2% in the same time frame. The company, with a market capitalization of $11.41 billion, is one of the largest integrated providers of products and services fo ...

Revenue Details Fresenius Medical implemented a new operating model during the first quarter and started reporting under two new segments, Care Delivery and Care Enablement. Previously, the company reported under the Health Care Products and Health Care Services segments. The Care Delivery segment primarily consists of products earlier reported under Health Care Services. International sales declined 18% reportedly as well as at cc but gained 3% on an organic basis. The decline was driven by divestments clo ...